[Home ] [Archive]    
:: Main About journal Editorial Board Current Issue Archive Submit an article Site Map Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Editorial Board::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 9, Issue 3 (10-2020) ::
Int J Med Invest 2020, 9(3): 1-4 Back to browse issues page
An early Bayesian Network Meta-analysis of Coronavirus Diseases 2019 (COVID-19) clinical trials
Farshid Javdani * , Mohammad Hashem Abdi , Samaneh Abiri , Marzieh Haghbeen , Ahmad Rastgarian , Mohammad Hasan Damshenas , Pouyan Keshavarz , Mohammad Amin Akbarnejad , Naser Hatami , Sayyed Reza Ahmadi , Seyed Reza Habibzadeh , Neema John Mehramiz , Mahdi Foroughian , Navid Kalani
Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
Abstract:   (3974 Views)
In this paper, we conducted a Bayesian Network Meta-analysis of the latest COVID-19 clinical trials including 5 studies on 591 patients receiving 4 different agents of Arbidol, Favipiravir, lopinavir- ritonavir, and Hydroxychloroquine and standard treatment protocol. We ranked the best agent based on patient improvement using Markov-Monte-Carlo-Chain. Hydroxychloroquine showed the best efficiency following the Favipiravir, Arbidol, lopinavir-ritonavir, and standard regimen in the first week of treatment. In the second week, with excluding Hydroxychloroquine arm (as some reporting studies hadn't addressed its efficacy in the second week), Favipiravir was the best treatment following by lopinavir-ritonavir, standard care, and Arbidol. As we saw a huge change in the ranking of the drugs by evaluating outcomes in the second week of treatment, we think that COVID-19 randomized clinical trials should be performed based on a standard study protocol worldwide, that could help  policy makers to make a decision on the treatment protocol.
Keywords: Network Meta-analysis, Favipiravir, SARS-CoV-2, COVID-19, lopinavir-ritonavir.
Full-Text [PDF 157 kb]   (1261 Downloads)    
Type of Study: Research | Subject: General
Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Javdani F, Abdi M H, Abiri S, Haghbeen M, Rastgarian A, Damshenas M H, et al . An early Bayesian Network Meta-analysis of Coronavirus Diseases 2019 (COVID-19) clinical trials. Int J Med Invest 2020; 9 (3) :1-4
URL: http://intjmi.com/article-1-517-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 9, Issue 3 (10-2020) Back to browse issues page
International Journal of Medical Investigation
Persian site map - English site map - Created in 0.04 seconds with 37 queries by YEKTAWEB 4645